ProtAffin Biotechnologie AG, a company developing biological products with the novel anti-inflammatory mechanism of action of targeting cell surface carbohydrate structures called glycosaminoglycans (GAGs), today announced the appointment of an internationally recognised Scientific Advisory Board and a Supervisory Board.
